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Resumo:     A malária é uma doença negligenciada que afeta mais de 100 países e ameaça 
metade da população mundial. Esta doença é transmitida pela picada do mosquito 
Anopheles, causando a infeção dos glóbulos vermelhos. O parasita da malária, 
Plasmodium, pertence à família dos protozoários, sendo por isso um organismo 
eucariota. Durante a invasão dos eritrócitos, o parasita degrada hemoglobina para 
obter nutrientes, contudo é libertado o grupo heme que é tóxico para a membrana 
do mesmo. Para ultrapassar os efeitos tóxicos do grupo heme, o parasita converte-
o num pigmento insolúvel, a hemozoina. Análogos sintéticos de porfirinas podem 
ser usados como alternativa a combater a malária, uma vez que são estruturalmente 
idênticos ao grupo heme. Assim, o presente trabalho teve como objetivo a síntese 
de novos conjugados porfirínicos com fármacos já usados na prevenção da malária. 
Para isso usou-se a 5,10,15,20-tetrakis (pentafluorfenil) porfirina (TF5PP) 
(composto 1) como porfirina inicial e sintetizaram-se novos derivados porfirínicos 
formados por conjugação da porfirina com três fármacos diferentes já usados na 
prevenção da malária: a primaquina (composto 3), a mefloquina (composto 5) e o 
artesunato (composto 9). A reação de conjugação para os dois primeiros compostos 
teve como base uma reação de substituição nucleofílica. A síntese do último 
conjugado não foi alcançada com sucesso. Posteriormente, foram sintetizados os 
complexos de Fe(III) dos três compostos obtidos: 1, 3 e 5.  
Para avaliar a possível utilização destes conjugados monitorizou-se a peroxidação 
em lipossomas constituídos por dois fosfolípidos, 1,2-dimeristoil-sn-glicero-3-
fosfocolina (dMPC) (lípido saturado) e a 1-palmitoil-2-linoleoil-3-fosfocolina 
(PLPC) (lípido insaturado). Os lipossomas foram incubados com os diferentes 
compostos, na presença e na ausência de H2O2, e a reação foi controlada por 
espectrometria de massa em modo positivo (ESI-MS). Através da razão 
[dMPC+H]+/[PLPC+H]+ foi possível avaliar a extensão da reação. Apenas os 
complexos de ferro dos compostos 1, 3 e 5 (respetivamente os compostos 2, 4 e 6) 
mostraram ter capacidade para oxidar a PLPC e na presença do composto 2 houve 
um maior aumento da razão [dMPC+H]+/[PLPC+H]+. Verificou-se que este 
composto na ausência de H2O2 é mais eficaz que os compostos 4 e 6, tanto na 
presença como ausência de peróxido de hidrogénio. Os produtos de oxidação 
obtidos na presença dos diferentes complexos mostraram a presença de um, dois e 
três átomos de oxigénio e a sua formação poderá ter sido mediada por espécies oxo 
de alta valência ou via peroxidação lipídica induzida por radicais.  
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Abstract:        Malaria is a neglected disease that affects more than 100 countries and threatens 
half of the world population. The disease is transmitted through the bite of an 
infected female mosquito Anopheles, causing infection of erythrocytes. The 
malaria parasite, Plasmodium, belongs to the family of protozoa, and so is a 
eukaryotic organism. During the invasion of the erythrocytes, the parasite 
degrades hemoglobin to obtain nutrients, yet is released the heme group that is 
toxic to parasite membrane. To overcome the toxic effects parasite converts free 
heme into an insoluble pigment called hemozoin. Synthetic analogs of porphyrins 
can be used as alternative to combat malaria, since they are structurally identical 
to the heme group. The present study aimed to synthetize new porphyrin 
conjugates with drugs already used in the prevention of malaria. For that, it was 
used 5,10,15,20-tetrakis (pentafluorophenyl) porphyrin (TF5PP) (compound 1) as 
a starting porphyrin and it were synthetized new porphyrin derivatives formed by 
conjugation with three different drug, primaquine (compound 3), mefloquine 
(compound 5) and artesunate (compound 9). The reaction for the first two 
compounds was based on a nucleophilic substitution reaction. The synthesis of 
compound 9 was not achieved. Subsequently, the Fe(III) complexes of the three 
compounds: 1, 3 and 5 were synthetized.  
To evaluate the possible use of these conjugates, lipid peroxidation was evaluated 
in liposomes constituted with two phospholipids: 1,2-dimyristoyl-sn-glycero-
3-phosphocholine (saturated lipid) and palmitoyl-lineloyl-
phosphatidylcholine (unsaturated lipid). Liposomes were incubated with the 
different compounds in the presence and in the absence of H2O2 and the reaction 
was monitored by mass spectrometry in positive mode (ESI-MS). Through the 
ratio [dMPC+H]+/[PLPC+H]+ it was possible to evaluate the extent of reaction. 
Only the iron complexes (compounds 2, 4 and 6) showed to have the ability to 
oxidize PLPC and in the presence of compound 2 there was a greater increase in 
the ratio [dMPC+H]+/[PLPC+H]+. It was verified that this compound in the 
absence of H2O2 has greater oxidation than compounds 4 and 6, both in the 
presence or absence of hydrogen peroxide. The oxidation products obtained in 
the presence of the different complexes showed the presence of one, two and three 
oxygen atoms and their formation may have been mediated by high valent oxo 
species or through radical-induced lipid peroxidation. 
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Preface  
Malaria is a disease that affects most developing countries and consequently the 
investment in the treatment is low leading to a high mortality rate.  It is important to 
develop new strategies to combat this disease once the parasite has already developed 
resistance mechanisms to some of the drugs used nowadays. Malaria parasite invades the 
erythrocytes and degrades hemoglobin to obtain nutrients. To overcome the toxic effects 
parasite converts free heme into an insoluble pigment called hemozoin. So, the strategy 
proposed for this work involved the synthesis of new conjugates based on porphyrins and 
some drugs already used in malaria treatment and to evaluate their ability of oxidize 
phospholipids present in parasite membrane. In the next sections of this introductory 
chapter some general aspects about malaria disease and treatment, porphyrins and their 
importance in oxidative process namely in lipid oxidation and mass spectrometry the tool 
used to follow lipid oxidation will be presented.  
 
1. Malaria, one of the neglected diseases 
Developing countries are mainly affected by a group of diseases called “neglected 
diseases” which include malaria, chagas disease, sleep disease, among others. These 
diseases lead to a high mortality rate in countries with negative economic impact and thus 
deserving an increased medical attention (1). 
Malaria affects more than 100 countries and threatens half of the world population, 
killing about 655 thousand people each year (1). According to the world malaria report, 
in 2012 there were nearly 210 million new cases and 80% of them were observed in the 
African continent, followed by Asia (13%) (2). The incidence of malaria increased 
between 2000 and 2005, although in 2012 it was observed a decrease of the number of 
cases (2). In Africa, this disease is the main cause of children death under 5 years old, 
killing a child every minute (1). There are many factors that affect the clinical outcomes 
of the disease, such as: geographic and social factors, like the access to treatment; parasite 
factors which include drug resistance, invasion pathways and multiplication rate; and 
finally host factors, for instance immunity, age, and pregnancy. This convergence of 
diverse factors can result from an asymptomatic infection to death (3). The symptoms of 
malaria do not appear with the mosquito bite, usually it takes ten to fifteen days to the 
first symptom appear. The most common symptoms are fever, headache, fatigue and 
vomiting (1,2).  
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Malaria is transmitted by a parasite called Plasmodium through the bite of an infected 
female mosquito Anopheles, causing infection of red blood cells (RBC’s) (1). In the 
following section it will be presented some detail about Plasmodium. 
2. Plasmodium, the parasite that causes Malaria 
The malaria parasite Plasmodium belongs to the genus protozoa and is a eukaryotic 
organism. Five different species of the parasite are able to affect humans which include 
P. falciparum, P. malariae, P. vivax, P. ovale and, more recently, P. knowlesi. The major 
responsible for the most severe cases and clinical worries of malaria are P. vivax and P. 
falciparum. However, it is P. falciparum that accounts for most of the mortality associated 
with the disease (1,4).  
Plasmodium enters the host organism by the mosquito bite. The injected parasites first 
invade the blood stream and then travel to liver, to hepatocytes, where there is a process 
of maturation to attack red blood cells. The different species of Plasmodium may have 
different ways of invasion, for example, P. falciparum can invade a large number of 
RBC’s while P. vivax only attacks reticulocytes, the precursors of  erythrocytes (3). The 
invasion allows the parasite to have access to a rich source of nutrients and gives 
protection from the immune system of the host. During this process, Plasmodium use 
their own machinery to identify the right cells, establish themselves and start the infection 
(5). 
2.1. Life cycle of Plasmodium parasites 
Malaria parasites have a complex life cycle involving both a vertebrate and an 
invertebrate host. The sexual phase of the life cycle happen inside the mosquito while the 
asexual phase begins when the parasite invades the RBC’s (6).  
The cycle begins in the invertebrate host and Plasmodium-infected mosquito injects 
the parasite forms, sporozoites, into the vertebrate host (figure 1). They can be placed 
directly on blood stream (less frequent) or on sub-cutaneous tissue, travelling then to the 
liver (7). Not all sporozoites migrate to the liver, some of them are inoculated by the insect 
and remain on the skin, growing at the place of inoculation (8). The co-receptor present 
on sporozoite membrane necessary for invasion involve both thrombospondin domains 
and thrombospondin-related adhesive protein (TRAP) (9). These domains bind to specific 
heparin sulfate proteoglycans present on hepatocytes. Within the hepatocyte, begins the 
formation of a parasitophorous vacuole (PV) (7) that provides the necessary conditions 
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to parasite replication, creating exoerythrocytic forms (EEF) which grow until the size of 
the parasite. The vesicles containing the parasites are called merosomes and once they 
reach the blood stream, burst and release erythrocytes-infected parasites, which are now 
called merozoites (10). The release of the merozoites marks the beginning of the infection 
and the appearance of the first symptoms. After merozoites spread into the blood stream, 
they are able to invade the erythrocytes, continuing the asexual stage of the cycle (figure 
1) (11).  
 
 
Figure 1 – Life cycle of malaria parasite (adapted from (12)). 
 
Hepatic stage is the first essential phase for the development of the parasite. It is in 
this stage that  Plasmodium gains the capacity to infect the RBC’s (10). In case of an 
infection by P. falciparum, it is predictable that each hepatocyte releases up to 40 
thousand merozoites (13). During the infections mediated by P. vivax and P. ovale, there 
are latent forms called hipnozoites that stay in the hepatocytes from variable time, causing 
disease relapses (14). 
The invasion of host cells by merozoites is driven by the parasite machinery and can 
be divided in several steps involving recognition, attachment and entrance to the 
erythrocytes; all these processes include a great number of proteins (5,6). The sequence 
of invasion is similar for all Plasmodium species. For the recognition process, were 
already identified some of the proteins involved. The merozoite surface proteins (MSP’s) 
link to the membrane via glycosylphosphatidylinositol (GPI) and the distribution along 
parasite membrane mediate the initial contact with the erythrocyte (figure 2a). This 
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process may occur at any point of the parasite surface. The attachment is followed by the 
apical reorientation before the parasite enters the cell and for that it was identified an 
apical membrane antigen 1 (AMA-1), which is required to establish the interaction (15). 
After the reorientation of the parasite, the initiation of the entry process occurs, which 
may involve direct interaction of ligands from the parasite with erythrocyte receptors 
(figure 2b). During this processes an irreversible convergence between membranes seems 
to occur, making this an irreversible step that leads the parasite infection. The invasion of 
the erythrocyte involves disruption of the PV and the host cell membrane. Duffy blood 
group (DBG) antigen is a receptor present in erythrocyte membrane and it appears to have 
a role in this membrane junction.  The connection between Duffy binding-like (DBL) 
protein family to the DBG antigen was first found on P. vivax (5,6). Homologous DBL 
proteins were also found in other species of Plasmodium. The erythrocyte binding antigen 
(EBA) was the first binding protein identified on P. falciparum and it is a sialic acid 
binding protein that binds specifically to glycophorin A, a sialoglycoprotein present on 
the erythrocyte membrane (16). Some proteases may have a role on the disruption of the 
erythrocyte membrane (figure 2c) (6). When the parasite invades the erythrocyte it is also 
formed a parasitophorous vacuole to form a favorable location for his development, that 
surrounds the parasite (5).  
 
      a) Initial contact           b) Apical reorientation       c) Junction formation and parasite invasion 
 
Figure 2 – Representation of the mechanism of erythrocyte invasion (adapted from 
(17)). 
In the blood stream, some of merozoites develop into gametocytes, that are the sexual 
forms of the parasite (18). These can be taken up by other mosquitoes during a blood 
feeding, developing then into gametes already inside the insect. Afterwards, the 
sporozoites are developed and injected during the next blood meal. The other merozoites 
are able to produce more merozoites per mature parasite, each one invading other RBC’s. 
Once inside the erythrocyte, the merozoite develop first to a ring form and then to a 
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thropozoite form. Thropozoite form then evolves to a schizont stage which can divide 
several times and produce new merozoites (6).  
During the invasion is formed the PV and the parasitophorous vacuole membrane 
(PVM) that surrounds the parasite and it is necessary for his development (19). At earlier 
stages of the development, ring-stage and thropozoite, it is formed a digestive vacuole 
(DV) with a lower pH, also called food vacuole, where is alleged to occur the digestion 
of hemoglobin. Hemoglobin degradation occur firstly in pre-DV vesicles that merge with 
each other and form a central DV (19,20).  
2.2. Hemozoin: malaria pigment 
Hemoglobin covers 95% of all cytosolic proteins of red blood cells (21) and during 
the intraerythrocyte cycle of the parasite at least 95% is converted to hemozoin (22,23), 
since almost host cell cytoplasm is consumed. Hemoglobin from RBC’s is ingested by 
parasites, into the food vacuole, where is degraded by proteases, releasing heme group. 
Different mechanisms of oxidation by heme ion have been described, which involve the 
formation of free radicals that are harmful for parasite membrane. Free heme is a 
lipophilic molecule and can interact with membrane, promoting lyses of the same by the 
oxidation of lipid content, leading to parasite death (24). In order to overcome this 
process, the parasite developed mechanisms to avoid damage of the membrane, by 
inducing heme polymerization to an insoluble pigment, called hemozoin, which cannot 
damage the erythrocyte membrane, allowing the survival of the parasite (25).   
Production of malaria pigment is the main fate of heme, which is almost entirely 
converted to hemozoin (22). Hemozoin consists only of iron(III) complex of 
protoporphyrin IX (Fe(III)PPIX), the molecules are connected to each other through the 
interaction of the propionate group of one Fe(III)PPIX and the Fe(III) center of another. 
One dimer of Fe(III)PPIX is called β-hematin, and hemozoin is a polymer consisting of 
infinite dimers of β-hematin connected by hydrogen bonds (26). Some evidences suggest 
that hemozoin formation is mediated by lipids (27). Inside the food vacuole, neutral lipid 
bodies are formed where hemozoin is incorporated. Lipid environment promotes the 
interaction between the molecules of Fe(III)PPIX (28). These lipid bodies may also be a 
protection to heme group, that can be degraded when in contact with hydrogen peroxide 
(H2O2) (29).  
I. Introduction 
 
8 
 
The hemozoin formation is a mechanism of defense from the parasite to avoid the 
damage promoted by free heme. Some therapeutic strategies against malaria have this 
pigment as the base of action, inhibiting its formation (23).  
 
2.3. Malaria treatment 
As soon as malaria is first diagnosed, it is necessary to determine if the infection is 
driven by P. falciparum or non-falciparum and if it is severe or not. Evolution of the 
disease it too rapid and  due to complex life cycle of the parasite, patients can rapidly be 
in a worse state than the day before even with an adequate treatment (4). A great challenge 
about malaria treatment is the fact that the parasite became resistant to different kind of 
drugs (30). The most problematic specie is P. falciparum, since it has already been 
observed resistance with different kind of treatments such as chloroquine, sulphadoxine-
pyrimethamine and mefloquine (figure 3) (30).  
 
 
 
Figure 3 – Structure of compounds used against Malaria. 
 
Chloroquine was, from decades, the most effective drug against malaria but when P. 
falciparum became resistant, other strategies to control the disease had to be applied. 
Despite this fact, the drug is still used to fight P. vivax infections and in America it is still 
therapeutically efficient. Nowadays, a different treatment is used based on a combination 
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of some drugs, as is the case of mefloquine and primaquine with artemisinin (figure 3), 
called artemisinin combination therapies (ACT’s). In 2012, ACT’s had been adopted as 
the first line treatment in about 80 countries where P. falciparum is prevalent (Table 1) 
(2).  
Anti-malarial drugs have different ways of action, and can act on different stages of 
parasite life cycle (31). Artemisinin is a drug effective against multi-resistant strains of 
P. falciparum and has a high specificity to Plasmodium, in both sexual and asexual phase. 
It is able to reduce the spread of the disease in low transmission areas (32). 
The exact mechanism of action of artemisinin is not well stablished, but it is thought 
that the endoperoxide bridge from the molecule is necessary for its antimalarial activity 
(33). Free heme interacts with artemisinin and it is necessary for the drug activation, 
promoting then the formation of free radicals that may interact with parasite proteins and 
lipids. (32,33).  Besides the fact of the production of free radicals, the interaction with the 
metal also inhibits the formation of the hemozoin pigment (33). The association to the 
iron metal is a necessary phase for the drug to become covalently bound to parasite 
macromolecules. Hartwig et al (34) suggested that artemisinin accumulate in neutral 
lipids and cause oxidative membrane damage.  
Chloroquine, mefloquine and primaquine are antimalarial drugs from the class of 
quinolines and, the mechanism of action is, in part, similar to artemisinin, due to the 
interaction with heme (29). These molecules form a drug:heme complex into the growing 
polymer of hemozoin, blocking the polymer extension (35). The fact that artemisinin has 
a rapid range of elimination and is combined with other drugs, makes this therapy the best 
way to avoid the development of resistance mechanisms by the parasite (32).  
Plasmodium strains differ in prevalence and so in the treatment applied. Table 1 shows 
the number of countries from the different regions where the strains are prevalent and 
also the treatment adopted.  
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Table 1 – Countries adoption policies for malaria treatment and prevalence of the transmission 
(adapted from (36)) 
Policy AFR AMR EUR SEAR 
Number of countries with ongoing malaria 
transmission 
45 21 3 10 
Number of P. falciparum endemic countries 44 18 - 9 
Number of P. vivax endemic countries 7 20 3 10 
ACT for treatment of P. falciparum 43 9 1 9 
Treatment with quinine/artemether 
IM/artesunate suppositories 
40 4 - 5 
Direct treatment with Primaquine 3 11 3 3 
Primaquine used on P.vivax cases 7 20 3 10 
AFR-African region; AMR- American region; EUR- European region; SEAR- South-East Asia region 
 
As seen from the table, P. falciparum is more prevalent in African continent and P. 
vivax in American continent. Besides the ACT treatment in African continent, quinine, 
artemether intramuscularly (IM) or artesunate suppositories are also adopted by 33 
countries in this region. Primaquine is most widely used with ongoing P. vivax 
transmission (2).  
 
2.4. Resistance mechanism 
Drug-resistant falciparum malaria is one of the bigger obstacles to world health. There 
were already verified resistance mechanisms, mainly from P.falciparum, with quinolone 
family and antifolates (37). The resistance developed is mainly due to mutations in genes 
encoding to proteins or enzymes necessary to the drug action (31,37).    
Regarding the case of chloroquine, the resistance mechanism involves the reduction 
of drug in food vacuole, and is associated to multi gene mutations (31). The chloroquine 
resistance mechanism is not seen in the same way between authors. Some researchers 
believe that is an increase of the drug efflux (38) while others suggest that the low levels 
accumulated in food vacuole are more important (39). Two different transporters have 
been identified on food vacuole and may have been associated with the mechanism of 
resistance, CRT (Chloroquine-resistance transporter) and MDR1 (Multi-drug resistance 
gene-1) (30,40).  
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The fact that parasites started to become resistant to some drugs, other ways to combat 
the infection have become prevalent, like combination of drugs (ACT’s) (2) . Heme 
group, as it was already referred, is toxic to parasite membrane and synthetic analogs of 
porphyrins, with a similar structure when compared to the heme, may be an alternative as 
a therapeutic approach to combat the malaria parasite at blood stage of infection (41). The 
adopted treatments for the disease are mainly directed to the hemozoin formation (23,32) 
and membrane lipids are not yet considered a specific target for the treatment.  
 
3. Porphyrins and its biological importance  
Porphyrins are a class of organic molecules presenting a macrocycle structure 
composed by four rings of pyrrole type. The four rings are connected by four methinic 
carbons, creating a heterocyclic nucleus known as porphyrin (Figure 4a).  This nucleus 
can present different substituents in the peripheral positions and can occur naturally or be 
obtained by synthesis. The presence of four nitrogen atoms inside the ring allow the 
formation of a complex with metallic ions, forming metalloporphyrins. Naturally, only a 
few metal ions can coordinate with porphyrins, as it is the case of magnesium, iron, zinc, 
manganese, copper, nickel and cobalt. Chlorophylls along with the heme group are the 
most abundant metalloporphyrins in natural systems. The heme group, the iron complex 
of protoporphyrin-IX (Figure 4b), is able to incorporate into proteins, being the prosthetic 
group of hemoglobin, myoglobin, cytochromes, catalases and oxidases (42). Hemoglobin 
is the most abundant protein in humans, has four heme groups in his constitution and 
develops many important functions in the body as the oxygen transport to the different 
tissues, being carried by erythrocytes, and is one of the major buffering systems of the 
body (43). Chlorophylls (Figure 4c) occur complexed with magnesium ion and some of 
them have one of the pyrrolic units reduced. (42).  
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Figure 4 – Structure of porphyrins ring (a), heme group (b) and chlorophylls (c). 
 
There are two different systems of nomenclature for these macrocycles, one proposed 
by H. Fisher and other by International Union of Pure and Applied Chemistry (IUPAC) 
(figure 5). According to Fisher nomenclature, the β (beta) positions of the pyrrole rings 
are numbered from one to eight and the methinic bridges, also known as meso positions, 
are nominated by the Greek letters α (alpha), β (beta), γ (gamma) and δ (delta). In the 
IUPAC system, all the positions are numbered from one to twenty four, including the 
nitrogen atoms. IUPAC system demonstrates to be foremost understandable once the 
nomenclature include all the atoms from the ring (42).  
 
Figure 5 – Representation of the two nomenclature systems used in porphyrins.  
The macrocycle core of porphyrin systems is highly conjugated, having thus some 
resonance forms. There are twenty two conjugated electrons pi but only eighteen of these 
are involved in the aromatic character of porphyrins. These compounds have an 
absorption spectrum very characteristic on the visible zone (42). The spectrum have an 
absorption band near 400 nm, called Soret band, and more four bands with superior 
wavelengths, called Q bands. Intensity, position and the number of these bands are 
influenced by the substituents on the ring and by the metal present inside the ring (42). 
Due to their properties, porphyrins can be useful in several distinct areas, however it is in 
medicine that the application of these compounds are more remarkable. In fact, 
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photodynamic therapy (PDT) is the most known application for porphyrins, it is used to 
treat cancer cells (44) and to photo inactivate microorganisms, virus (45–47) and protozoa 
(48,49).  These compounds have already been tested against the malaria parasite and have 
a potential effect on it, as it will be referred ahead (41,50,51).  
3.1. Porphyrins against Malaria 
The first report of the use of porphyrins against Malaria parasite was by Basilico et al 
(52), that used non-iron porphyrins and verified the inhibition of β-hematin 
polymerization. These authors tested porphyrins identical to heme group (figure 6a and 
6b), with the hypothesis that the interaction between the two porphyrins is possible by π 
– π interactions, which results in a heme:porphyrin complex (52). Recently, Abada et al 
(51) tested porphyrin derivatives against protozoa, being the most effective one the 
compound represented on figure 6c. In this case, it was verified a high selectivity to 
Plasmodium parasites and the activity against them was bigger than to other protozoa.  
 
Figure 6 – Porphyrin derivatives used against malaria. 
 
Cole et al (50), studied the activity of some metalloporphyrins, and justified the effect 
also via π interactions. Consequently, these porphyrins appear to be an ideal system to 
establish those interactions being powerful targets to stop hemozoin formation, leading 
the heme group available to destroy the parasite. These authors tested protoporphyrin IX 
(PPIX) (figure 6a) with various center metals: chromium, copper, cobalt, manganese, 
zinc, magnesium and tin. It was observed a total inhibition of heme polymerization by the 
compounds: Cr(III)PPIX, Co(III)PPIX, Mn(III)PPIX and Cu(II)PPIX. However, the 
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other complexes (with Zn, Mg and Sn) also show to be effective against formation of β-
hematin (50).  
The presence of the metal ion has an evident effect on PPIX connection with 
metalloporphyrins, being much more efficient than the corresponding free bases. 
Thereby, π-stacking interactions between porphyrins can be modulated by metal 
combinations (50). Other metal combinations with PPIX were also studied  by Begum et 
al (41), namely with silver, gallium and palladium. The most potent inhibitors of β-
hematin formation where those with the metals Sn and Ga. Some other compounds tested 
showed to be effective but in higher concentrations. In fact, some of the 
metalloporphyrins had strong activity against trophozoite (GaPPIX and SnPPIX), having 
a higher range than drugs used against malaria like artemisinin and chloroquine (41). 
Metalloporphyrins were proved to have potent activity by inhibiting heme 
polymerization, thus showing powerful antimalarial activity, being recognized as great 
inhibitors of β-hematin formation (41,50,51). Besides the fact that these compounds can 
inhibit hemozoin polymerization, the presence of the metal can also be favorable to the 
production of reactive oxygen species (ROS) leading to destruction of parasite membrane 
(53). 
 
3.2. 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin (TF5PP) 
In this work, the porphyrin used to synthetize the porphyrin derivatives was TF5PP. In 
fact, this porphyrin has been used to synthetize porphyrins derivatives bearing 
substituents in their para positions of the meso-aryl groups. This is due to its capacity to 
react with nucleophiles as amines and alcohols, among others, that are able to substitute 
the para-F atoms from the pentafluorophenyl groups (54).  
4. Eukaryotic membrane composition: lipids and lipid oxidation  
Lipids are compounds with a great chemical and functional diversity which, except for 
cholesterol, link fatty acids with different structures. The main classes of membrane lipids 
are glycolipids and phospholipids (55).  
Phospholipids are the major constituents of all cellular membranes, forming a semi-
permeable membrane to water and solutes, allowing the communication between cells 
(56). These biomolecules have the capacity of mediating regulatory functions in cells and 
may have a role in apoptosis and cell signaling (57,58). The most abundant class of lipids 
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in cells is glycerophospholipids, responsible to maintain the membrane integrity. 
Glycerophospholipids are constituted by a glycerol molecule that has two fatty acids 
linked in the positions sn-1 and sn-2 and a phosphate group in the sn-3 position. The 
phosphate group may be connected to polar molecules that determine the type of 
phospholipid. Hereupon, the polar molecules are choline, ethanolamine, serine, glycerol 
and inositol, resulting in the classes phosphatidylcholine (PC),   
phosphatidylethanolamine (PE), phosphatidylserine (PS),  phosphatidylglycerol (PG), 
phosphatidylinositol (PI), respectively, and with no head group phosphatidic acid (PA) 
(figure 7) (55,56). From the different classes of glycerophospholipids, PE and PC are the 
most abundant in cellular membranes of eukaryotic organisms (55,58). The link between 
glycerol and fatty acid in sn-1 position may occur by an ester bond, called phosphatidyl; 
by an alkyl-ether bond, named plasmanyl or by a vinilic-ether bond designated by 
plasmenyl (59).  
 
 
Figure 7 – Representation of different phospholipid classes   
 
Membrane fluidity depends of the lipid composition, mainly phospholipids and 
cholesterol content (60). Phospholipids have distinct physical characteristics, including 
the capacity to bind cholesterol due to the level of unsaturation. The presence of 
unsaturated fatty acids, predominantly with cis conformation, increases the membrane 
fluidity when compared to membranes only constituted by saturated fatty acids (55). Each 
phospholipid has an individual influence on the membrane fluidity which should be 
known and considered. Thus, choline group of PC is large, increasing the membrane 
fluidity. On the other hand, PE reduces the fluidity because ethanolamine is a small 
molecule, making the area of the fatty acyl chains bigger compared to head group. 
Although, the shape does not determine fluidity itself, some other factors like hydration 
and the level of unsaturation also have a role in membrane fluidity (61).  
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4.1. Membrane composition of Plasmodium 
Plasmodium is a eukaryotic parasite and his plasma membrane has the same 
constitution as the most eukaryotic organisms. PC and PE are the major phospholipids of 
cellular membrane (57), PC accounts for about 56% while PE represent about  27%  of 
the total phospholipid composition (62). Other phospholipids are present in his 
membrane, and PS and sphingomyelin (SM) are those that are present in a higher range. 
Phospholipid composition of uninfected erythrocytes is much different from the one of 
purified parasite. Parasite contains almost the double of PC, three times more PI and less 
SM and PS than erythrocytes. However, when P. falciparum infects the erythrocytes it 
induces some modifications on erythrocyte membrane composition and the lipid content 
is significantly adjusted (62).  
This alteration perhaps occurs as a result of the effect of parasite metabolism on 
erythrocytes lipids or by the trafficking of lipids between the parasite and erythrocytes 
membrane (62,63). Looking to the malaria infected erythrocytes, there are two different 
membranes: infected erythrocytes plasma membrane (IEPM) and PVM that surrounds the 
parasite. There is a decrease of the ratio cholesterol/phospholipid in infected cells by P. 
falciparum, leading to an alteration on membrane fluidity (64). Hsiao et al (62) 
demonstrated that some classes of lipids are altered on IEPM. Compared to normal 
erythrocytes, IEPM has higher content of PC and PI, and a lower content on SM and PS. 
Parasite uses its synthetic capability to promote modifications on membrane of 
erythrocytes, due to the presence of enzymes with the capacity to synthetize 
glycerophospholipids (63). It was also verified a decrease of polyunsaturated fatty acids 
(PUFA) and thus the membrane became less fluid. It seems that the erythrocyte 
membrane become more likely to parasite membrane. However erythrocyte membrane 
integrity is maintained by some compensatory changes, as is the case of the reduction of 
SM content (62). 
Phosphatidylcholine is one of the major constituents of parasite membrane and due to 
this fact it is a molecule to have in attention. During the invasion process there is an 
insertion of host PC into the PVM, and this showed to be essential to parasite maintain 
protein composition and to avoid host cell elimination mechanisms. PC depletion also 
appear to affects the trafficking of proteins to parasite surface. The presence of proteins 
in PVM seemed to be indispensable for parasite to avoid the elimination by erythrocytes, 
which may be an explanation to why PC plays a critical role in parasite survival (63).  
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Thus, as PC plays a crucial role to parasite survival and multiplication, it should be 
consider a potential target to new therapeutically drugs. This work will focus on the 
porphyrin ability to oxidize parasite membrane.  
 
4.2. Phospholipid oxidation 
Phospholipids are molecules susceptible to oxidation, creating modifications in 
oxidative conditions and during the reaction with ROS, producing new compounds. 
Resulting products from the oxidation are structurally different and have distinct 
biological activities (65,66). Lipid peroxidation may be initiated by any specie that has 
the capacity to withdraw a hydrogen atom from the polyunsaturated fatty acids (PUFA) 
of the side chain of membrane lipids (67). 
Oxidative modifications of phospholipids depend on the nature of the oxidant and it 
determines the oxidative reactions. Oxidation may result from chemical reactions, by 
radicals or by enzymes and it is also associated with age related diseases (65). Radical 
species tend to be more reactive but less selective than non-radical species. These last are 
able to diffuse from the point of origin. Consequently, the concentration and the nature 
of the oxidizing species are important, as well as the presence of antioxidant molecules. 
Low levels of H2O2 may disrupt the formation of the hydroxyl radical by Fenton reaction 
and consequently compromise phospholipid peroxidation reactions. A higher 
concentration of O2 compared with less H2O2 suggests that iron complexes may have a 
higher role in the oxidation compared with hydroxyl radical (67).  
 
4.2.1. Iron porphyrins as lipid oxidants 
Cytochromes P-450 (CYP) family of enzymes are monooxygenases linked to plasma 
membrane.  Being much like to heme group, the mechanism of oxidation mediated by 
CYP’s is similar to that what may happen in parasite membrane. This enzymes have been 
associated to processes like hydroxylation and epoxidation of aliphatic groups (68). The 
mechanism of action of CYP’s is represented on figure 8. 
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Figure 8 – Catalytic cycle of CYP (adapted from (69)).  
 
The cycle represented in figure 8 shows two possible pathways in substrate 
hydroxylation, using molecular oxygen or peroxides. Explaining the long pathway (from 
1 to 6 reactions), firstly Fe(III) is reduced to ferrous state (Fe(II)) (step 1) that has affinity 
to oxygen, forming a ferric superoxide complex (step 2). Afterwards, occurs a reduction 
of the formed specie followed by protonation of the same, allowing the heterolytic 
cleavage of O-O bond (steps 3 and 4). During the reaction 4, the intermediates: 
[(Porphyrin)Fe(V)=O] or [(Porphyrin)Fe(IV)=O] •+ can be formed, being responsible for 
substrate oxidation (70), transferring the oxygen atom to the substrate. The last step of 
the reaction is the regeneration of the initial compound. The peroxide shunt is a shorter 
pathway that involves the same intermediates formed in step 4, but there is a direct 
formation of those from the Fe(III) complex, in the presence of peroxides. This 
mechanism proposed for CYP can be associated with Fe metalloporphyrins, as the 
catalytic center is the same. However, different mechanisms have been proposed for the 
mechanism of oxidation by iron porphyrins (24). In Fenton-like mechanism (figure 9), it 
is formed a hydroxyl radical, that is able to start the mechanism of lipid peroxidation. 
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Catalysis mediated by this mechanism results in a rapid regeneration of Fe(III) due to the 
high oxygen affinity (24).  
 
Figure 9 – Representation of Fenton-like mechanism (24).   
 
Other proposed mechanisms of oxidation involves higher states of oxidation of the ion 
(figure 10) (24). The most accepted mechanisms for reactions of epoxidation and 
hydroxylation by metalloporphyrins are represented on figure 10. These mechanisms are 
the same as those explained in the mechanism of CYP (24,68). The ability of 
metalloporphyrins to oxidize several biomolecules makes them good candidates to being 
used in biomimetic catalysis.  
 
Figure 10 – Possible mechanisms of epoxidation and hydroxylation by porphyrins 
(adapted from (69)). 
 
As a consequence of lipid oxidation, the modifications induced in membrane lipids 
result in a high variety of products structurally different among each other and from the 
precursor (71). Thereby, the polarity and the shape are changed, leading to loss of the 
physic and functional properties of the membranes where they are in.  It is also possible 
that the interactions between the molecules change the selective permeability with a 
consequent increase of the penetrability, loss of symmetry and ionic hemostasis, 
interaction lipid-lipid and lipid-protein and reduce of membrane fluidity (72).  
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In the course of oxidation, new oxidation compounds are formed, resulting in a great 
diversity of compounds that are classified according to the type of modifications. The 
resulting products may be called long chain products if the phospholipid chain is 
preserved and has extra number of oxygen atoms, resulting in an increase in phospholipid 
mass; short chain products if the phospholipid is broken down by oxidative cleavage that 
may have terminal aldehyde or  carboxylic group; and adducts, which result from reaction 
between resulting products of oxidation and carbonyl and amino groups from adjacent 
biomolecules (71,72). The presence of these phospholipids in membranes may cause 
disequilibrium on membrane permeability due to alteration of fluidity and packing of 
phospholipids (61), which may induce apoptosis (65). 
 
4.2.2. Phosphatidylcholine oxidation 
Phosphatidylcholine is the main component of Plasmodium membrane. It has a fatty 
acyl chain unsaturated, making the process of oxidation favorable. Radical peroxidation 
affect the physical properties of the membranes which is reflected in membrane integrity 
and permeability (73).  
Tandem mass spectrometry is widely used in the identification of resulting products 
from the oxidation of phospholipids (73–76). Glycerophospholipids as the main class of 
phospholipids in membranes is the most studied class by mass spectrometry. Reis et al 
(74) studied long chain products of palmitoyl-lineloyl-glycerophosphatidylcholine 
(PLPC) liposomes using liquid chromatography coupled to tandem mass spectrometry. 
Linoleic acid has two unsaturations and is susceptible to suffer oxidation, whereas 
palmitoyl is a saturated acid and is less susceptible to be oxidized. They found products 
resulting from the insertion of one to five oxygen atoms in sn-2 position. The same 
authors also used electrospray tandem mass spectrometry to identify short chain products 
of phosphatidylcholine (76). Therefore, mass spectrometry is a very powerful and useful 
technique in the identification of several compounds formed during oxidation (74).  
 
5. Mass spectrometry  
Mass spectrometry was discovered by J. J. Thomson and F. W. Aston in the beginning 
of twentieth century, being nowadays one of the most sensitive techniques in the 
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characterization of a great diversity of biomolecules like lipids and proteins. This 
technique is a quantitative and qualitative method in the analysis of ions, being quick and 
selective. The base of mass spectrometry is the separation of ions according to its atomic 
mass (m) and his electric charge (z) (77).  
A spectrometer is constituted by three essential parts: ionizing font, an analyzer and a 
detector (figure 11). The sample is introduced on the ionizing font, where the ionization 
of the molecules occur and the ions are conducted to the analyzer where they are separated 
by their mass/charge (m/z) ratio. It is necessary to have a vacuum pump to control the 
pressure within the mass spectrometer. Low pressure is necessary to limit the collisions 
due to the possibility of produce unwanted products or loss of charge. Subsequently they 
are detected on the detector, where the results are shown by the form of a spectrum, which 
have the mass of ionic products (as m/z ratio) on the abscissa and their relative abundance 
on the ordinate. The mass spectrometer is usually connected to a computer to process and 
record data (77,78). 
 
Figure 11 – Typical components of a mass spectrometer: ion source to ionize the 
sample; mass analyzer to separate the compounds and the detector (adapted from (59)).  
 
The first spectrometers only had the capacity to analyze a restricted range of 
compounds, with low molecular weight and volatiles. On the other hand, due to the high 
energy transferred, the ions were fragmented. Therefore, it have emerged new ionization 
techniques that allow the analysis of bigger molecules, nonvolatile and also mixtures (79). 
There are different soft ionization methods that include fast atom bombardment (FAB), 
electrospray ionization (ESI) and matrix-assisted laser-desorption ionization (MALDI). 
The variety of ionization methods has expanded the ability of detection an analysis of a 
wide variety of lipids with different sizes (80). These ionization methods promote the 
protonation or deprotonation of the compounds, but limits the structural classification of 
the products, since it only gives information about the molecular weight of the 
compounds.  In a way to reverse this limitation as surged the tandem mass spectrometry, 
which is essential in the analysis of a great variety of compounds, like proteins (79) and 
phospholipids (80).  
Sample 
introduction Ionization
Mass 
analyzer
Ion 
detection
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Nowadays, the most used ionization techniques are ESI and MALDI (77). MALDI is 
mostly used in bigger molecules, in the study of proteomic but is less used in the analysis 
of phospholipids. (59). For this reason, it will be explained the ESI method since it is the 
most used in analyses of phospholipids and it also is the method used in this work. 
 
5.1. Electrospray ionization (ESI) 
ESI was initially discovered by John Fenn (77) and has been used in analysis of several 
compounds like proteins, peptides, sugars and phospholipids (81). The difference in 
functional groups and molecular weight leads to different ways of ionization. Small 
molecules usually form ions with a single charge: [M+H]+ or [M-H]-, while bigger 
molecules had the tendency of forming multi charged ions (77).This characteristic is an 
advantage in the analysis of high molecular weight molecules once the m/z values are 
lower and can be detected even in spectrometers with low detection limits, increasing the 
range of the molecules that can be analyzed (82). 
Ionization by electrospray occur in different phases: formation of the electrospray and 
vaporization of the solvent in a way to obtain ions is gaseous phase (78). In an ESI source, 
the sample is ionized when is emitted from a capillary with voltage applied to it. This 
process forms a spray which contain charged droplets that are dessolvated and reduce its 
size as travel down for pressure and potential gradient (77,83). The voltage applied may 
be positive or negative, it depends on the pretended analyze (ESI positive or negative 
mode) (81), that will generate a gradient to separate the charges on liquid superficies 
which results in the projection of the same out of the capillary (Taylor cone) (figure 12) 
(77). The formation of the droplets results in the combination of the voltage applied and 
an inert gas, that favors the formation of ions in gaseous phase, which are then analyzed 
(83). To the spectrometer may be coupled different analyzers, being the most common 
ones the quadrupole (Q), ion trap and TOF (time of flight) (77). 
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Figure 12 – Schematic representation of ESI process of ionization (adapted from (81)).  
 
5.2. Tandem mass spectrometry (MS/MS) 
Tandem mass spectrometry has surged from necessity to overcome the lack of 
compounds structural information. In this technique is selected a precursor ion in the first 
analyzer (Q1), which will be fragmented in a collision cell (Q2). The fragments are 
analyzed in the second analyzer (Q3) (figure 13). The second analyzer may be also 
programed to select one single ion, if it was pretended to see one single fragment. This 
method is able of isolating ions, fragmenting them and measure the m/z of resulting 
products.  
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Figure 13 – Mass spectrometer with triple quadrupole, where Q1 and Q3 are analyzers 
and Q2 a collision cell (83). 
 
During the process of collision, in the presence of an inert gas, part of the energy of 
the precursor ion may be converted into internal energy, promoting an exciting state on 
ions, which are fragmented by a process named collision-induced dissociation (CID) (81). 
The most utilized equipment’s nowadays in analyzes by MS/MS include hybrid 
analyzers like Q-TOF, triple quadrupole and ion trap. Ion trap analyzers are more recent 
and allow to realize a MS/MS analyzes with only one analyzer, once the analyzer has the 
capacity of retain the selected ions making them to collide with the gas in the same 
camera. Furthermore, is also possible to maintain any of the fragmented ions in the trap 
and repeat the process of collision to analyze this new ion. This can be called MS/MS/MS 
(MS3) and can be obtained a sequential information of the precursor ion and its fragments 
(77,82). Tandem mass spectrometry (MSn) allows the achievement of structural 
information compounds of interest by fragment analysis of precursor ion (79). 
 
6. Aims 
This work is based on the search of new synthetic procedures leading to new 
compounds with ideal properties for being used in the treatment of malaria. The aim is to 
act in the blood stage of infection stage where occurs the interaction of antimalarial drugs 
with the heme group (29), which is involved in the toxicity of the drugs in the parasite 
(53). During this stage of infection parasite degrades hemoglobin to obtain necessary 
conditions to survive, although during the process free heme is released. To overcome the 
toxic effects of heme group, the parasite induces heme polymerization to in insoluble 
pigment, hemozoin (25).   
Having these facts in mind, in this work it is aimed the synthesis of new hybrids 
consisting in conjugated units of Fe (III) porphyrin derivatives with drugs that have been 
showed to be effective in eliminating of malaria parasite, such as primaquine and 
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mefloquine (quinoline antimalarials) and artemisinin (32,35). It is expected that these 
hybrids can act both as drug delivers and as inhibitors of hemozoin formation. 
Furthermore, it is also expected that these new compounds became toxic only to the 
parasite, and not to the patient. The oxidation ability of porphyrins will be tested in 
biomimetic membranes. Due to the similar structure of heme group, these hybrids must 
have oxidative power toward membranes (53).  
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1. Synthesis of new anti-malarial porphyrin conjugates  
The synthetic strategy to obtain new anti-malarial porphyrin conjugates was based on 
the structures of the selected anti-malarial drugs primaquine (A), mefloquine (B) and 
artesunate (C) (Figure 14). In the selection of primaquine and mefloquine it was 
considered the already developed resistance of the parasite to these drugs (30) and it was 
envisaged the possibility that their conjugation to a porphyrin could revert this situation. 
On the other hand, the artemisinin derivative artesunate is one of the most prescribed 
drugs against malaria parasite (2,33) and the potentiation of its efficiency would be an 
important goal.  Considering the presence of the nucleophilic amino functions in the first 
two drugs, it was selected the 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin (1, 
TF5PP) in the design of conjugates 3 and 5. Considering the presence of the acid group 
in artesunate the conception involved the introduction of an amino spacer between the 
porphyrin and the drug in order to obtain compound 9 (Figure 14).  
As it was mentioned in the introduction, metalloporphyrins are potent inhibitors of 
hemozion (malaria pigment) formation  (41,50,51). So, the propose to synthetize the 
corresponding Fe(III) complexes 4 and 6 of the new porphyrin derivatives was based on 
that anti-malaria activity of metalloporphyrins. In the selection of these 
metalloporphyrins it was considered the oxidant power of the Heme group in membranes 
(53). The possibility to use TF5PP for further functionalization by nucleophiles is well 
documented  in literature  (54). The success of this porphyrin can be explained by the 
high reactivity of the para-fluorine in the C6F5 units to be substituted by different type of 
nucleophiles. In fact, the nucleophilic aromatic substitution of the para-F atoms is highly 
selective and normally occurs in a high yield. Additionally the number of substituents 
introduced can be controlled by the reaction time, the number of equivalents of the 
nucleophile and temperature.  
Actually, there are several reports of the para-substitution of fluorine atoms from 
TF5PP with amines and alcohols (54). The reaction of TF5PP, or of its metal complexes, 
with primary and secondary amines, leads to the selective substitution of the para-F atoms 
of one to four C6F5 groups of the starting porphyrin by amine groups in high yields 
(54,85). Considering this fact, the selective nucleophilic substitution of one of the para-
fluorine in compound 1 was considered in the design of conjugated 3, 5 and 9. 
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Figure 14 – Structure of the anti-malarial drugs and of the desired anti-malarial porphyrin 
conjugates. 
 
The synthesis and characterization of the new derivatives 3 and 5 and of their Fe(III) 
complexes 4 and 6 are presented in the following section. Posteriorly it will be also 
presented the attempts to obtain conjugate 9. 
 
1.1.Synthesis of porphyrin conjugates 2-6 
The synthetic strategy to obtain the new porphyrin/anti-malarial conjugates 3-6 
involved the experimental work summarized in Scheme 1. The key step was based on the 
selective nucleophilic substitution of the para-fluorine atom of one of pentafluorophenyl 
groups by primaquine (A) and mefloquine (B) affording respectively the free-bases 3 and 
5. This procedure was followed by the complexation of the free-bases with FeCl2 in order 
to obtain the corresponding iron(III) complexes 4 and 6.   
The coupling of the anti-malarial drugs A and B with porphyrin 1 was carried out in 
toluene at 120ºC and in the presence of a base (NaH for compound 5 and K2CO3 for 
compound 3). The progress of the reaction was monitored by TLC and was stopped when 
it was observed almost total consumption of the starting compound. The workup involved 
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the washing of the reaction mixture with distillated water, extraction with 
dichloromethane and purification of the crude residue by silica gel column using CH2Cl2 
as eluent.  
The desired compounds 3 and 5 were obtained pure in 67% and 47 % yield, 
respectively. The starting porphyrin was not totally consumed in these two reactions (in 
both cases the amount of the starting porphyrin was not determined). A compromise 
between an adequate consumption of the starting porphyrin and the formation of 
conjugates containing two or more units of the anti-malarial drugs had to be taken. 
Besides, the time of reaction of compound 3 formation was lower than the one to obtain 
compound 5. Probably the steric hindrance of the secondary amine from mefloquine is 
responsible for the lower yield and the higher reaction time (72h versus 18h of reaction).  
 
 
Reaction conditions: i) toluene, K2CO3, 120ºC, 18h; ii) toluene, NaH, 120ºC, 72h; iii) DMF, 
FeCl2, pyridine, 140ºC, 24h reflux. 
Scheme 1 
 
The methodology used for the synthesis of the iron(III) 4 and 6 was based on 
conventional procedures (86). The reactions between the free-bases 3 and 5 and FeCl2 
were performed in a mixture of dimethylformamide (DMF) and pyridine at 140ºC in 
reflux under inert atmosphere until the TLC and UV-vis controls confirmed the insertion 
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of the metal. After the metalation process, the solvents were removed under vacuum. The 
resulting solids were washed thoroughly with water, to remove the excess of the metal 
salt and compounds 4 and 6 were isolated with a yield of 14.4 % and 13.5 % respectively.  
For comparative studies complex 2 was also prepared from porphyrin 1 using the same 
procedure.  
The structures of the new porphyrin derivatives 3 and 5 were confirmed by UV-vis, 
1H, 13C and 19F NMR spectra and ESI-MS. The insertion of the metal in the inner core of 
free-bases 1, 3 and 5 was confirmed by UV-vis and ESI-MS.  
As an example, the absorption spectra of the new conjugates 1 and 2 is represented on 
figure 15 and show the expected Soret bands at 413 and 412 nm, respectively (42). In the 
Q-band region the number of bands is dependent on the absence or presence of Fe(III) 
ion in the porphyrinic core and also by the presence of the substituent. Compound 1 
(TF5PP) shows four Q-bands at 506, 540, 583 and 648 nm, its Fe(III) complex 
(compound 2) show only two Q-bands at 503 and 630 nm. It is observed a decrease in 
the number of Q-bands and a deviation of those to lower wave-lengths of the UV-vis 
spectrum of compound 2, indicating that the metalation occurred. 
 
 
Figure 15 – Uv-vis spectra of compounds 1 and 2 in CHCL3. 
 
In 1H NMR spectrum of conjugate 3 (Figure 16) it is possible to identify some 
characteristic peaks of the drug primaquine in the aliphatic zone. The doublet at δ 
1.44 ppm was assigned to the CH3 protons (E) and the multiplet at δ 1.93 – 2.04 
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ppm to the CH2 protons B and C of the aliphatic chain. The signal due to the protons 
A, J and D appear at δ 3.75, 3.90 and 4.32 ppm, respectively; the resonances due 
to the metoxy protons (J) appear as a singlet and the ones of A and D protons as 
multiplets. In the aromatic zone is also possible to identify some signals that 
correspond to primaquine, at δ 8.58 (F), δ 7.96 (H) and δ 7.32 (G) ppm as double 
doublets with J = 4.2 and 1.6 Hz, J = 8.3 and 1.6 Hz and J = 8.3 and 4.2 Hz, 
respectively. Plus, it is observed a peak corresponding to two hydrogens I and K 
more protected at δ 6.39 and 6.40 that is an AB system with a J = 2.5 Hz. The eight 
β pyrrolic hydrogens appear at δ 9.01, 8.90 and 8.85 ppm. Compound 3 shows a 
Soret band at 415 nm and three Q-bands at 508, 585 and 641 nm. By ESI-MS it 
was possible to identify the ions at m/z 1214.3 (M+H)+ and 607.7 (M+2H)2+, that 
confirm the molecular weight of the pretended compound. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 – 1H NMR spectrum (CDCl3) of compound 3. 
 
The 1H NMR spectrum of conjugate 5 present also characteristic signal in the 
aliphatic and aromatic zone. At higher δ, besides the signals of porphyrin β-pyrrolic 
protons, four more signals are present that correspond to the molecule of 
mefloquine. It is verified the presence of two doublets at δ 8.30 (J=8.0 Hz) and δ 
8.58 (J=8.0 Hz), one singlet at δ 8.33 ppm and a triplet at δ 7.90 ppm (J=8.0 Hz). 
The β pyrrolic protons appear at δ 8.82, δ 8.86 and δ 8.90 ppm. The aliphatic 
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protons from the mefloquine ring (C5H9N) appear at δ 1.42 – 1.80, δ 2.67 – 2.69, 
3.31 – 3.40 and δ 3.16 – 3.26 as multiplets and at δ 2.03 (J= 10.8 Hz) as a doublet. 
One more signal is observed at δ 6.43 (J=4.9 Hz) as a doublet. Compound 5 shows 
a Soret band at 413 nm and three Q-bands at 507, 583 and 637 nm in the UV-vis 
spectrum. By ESI-MS it was possible to identify the ions at m/z 1333.2 (M+H)+ 
and 667.1 (M+2H)2+, that confirm the molecular weight of the pretended 
compound. 
The UV-vis spectrum of the Fe(III) complexes of the compounds 3 and 5 present 
a Soret band at 416 and 413 nm, respectively. The Q-bands of compound 4 appear 
at 506 and 634 nm and of compound 6 at 506 and 628 nm.  
Additional the 19F NMR spectrum is an important tool to confirm the mono-
substitution of the fluorine atom of porphyrin 1. In the spectrum of TF5PP it is 
possible to identify three different signals due to the meta-F (δ -184.8 ppm), para-
F (δ -174.7) and orto-F (δ -160.0 ppm) with a ratio of 2:1:2. The covalent linkage 
of the drugs to the porphyrins was also proven by the 19F NMR spectra of the new 
conjugates comparing with the one of TF5PP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17 – 19F NMR spectrum (CDCl3) of compound 3. 
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In 19F NMR spectrum of compound 3 (Figure 17) is patent the asymmetry 
introduced by primaquine. The o-F atoms appear as two multiplets between δ -
159.82 and -159.52 and between δ -163.93 and -163.74 ppm. The resonance due to 
the o-F of the substituted ring appear slightly more protected. Next appear the p-F 
atoms at δ -174.73 and -174.52 ppm as a multiplet and the m-F atoms at δ -183.83 
as a large doublet and as a multiplet between δ -184.70 and -184.48 ppm. As 
opposite for the o-F atoms, the m-F atoms of the substituted ring appear slightly 
more deprotected.   
Compound 5 present additionaly peaks in 19F NMR spectrum (Figure 18) 
compared to compounds 3, due to the extra six fluor atoms in the structure of the 
drug mefloquine. The fluor atoms of the porphyrinic ring appear with a similar 
pattern to the one observed for compound 3, while the fluorine atoms of the 
mefloquine residue appear at lower chemical shifts, δ -90.89 and δ -83.35 ppm as 
singlets.  
 
 
Figure 18 – 19F NMR spectrum (CDCl3) of compound 5. 
 
1.2.Attempts to synthetize conjugate 9 
The synthetic approach to obtain the new porphyrin/anti-malarial conjugate 9 involved 
the experimental work summarized in Scheme 2. As artesunate can’t react directly with 
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the porphyrin, other strategies to the formation of the conjugate were attempted.  For that, 
it was used ethylenediamine to serve as spacer between the drug and the porphyrin, and 
an important step of the approach (ii) was similar to the one described for compounds 3 
and 5.   
 
Reaction conditions: i) THF, -10ºC; ii) Toluene, K2CO3, 120ºC reflux; iii) TFA, CHCl2, room 
temperature; iv) EDC, DMAP, CHCl3, room temperature.  
Scheme 2  
 
In the strategies proposed to obtain compound 9, one of the amino groups of 
ethylenediamine was protected with di-tert-butyl dicarbonate (BOC) to ensure that only 
one amine end is free to react with the porphyrin (scheme 2 i)). The reaction was carried 
out by the addition of ethylenediamine to BOC, in THF at -10ºC. The reaction mixture 
was stirred overnight at room temperature and the THF was evaporated under reduced 
pressure. Then, the reaction mixture was washed with distilled water and mono 
substituted ethylenediamine was extracted with dichloromethane and obtained pure with 
an 81 % yield. 
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In 1H NMR spectrum of the mono protected ethylenediamine (Figure 19) it is possible 
to identify some characteristic signals, as is the case of the singlet signal at δ 1.45 ppm 
that correspond to the 9 equivalent protons of BOC end. It is also possible to identify the 
signals from the ethylenediamine at δ 2.79 as a triplet (J=5.9 Hz) and δ 3.16 ppm as a 
quartet (J=5.9 Hz).  
 
 
Figure 19 - 1H NMR spectrum (CDCl3) of mono substituted ethylenediamine. 
 
The reaction between the protected ethylenediamine with the porphyrin was performed 
in toluene in the presence of K2CO3 at 120ºC (scheme 2 ii)). The evolution of reaction 
was controlled by TLC and it was stopped when it was observed a small amount of the 
starting porphyrin. The workup involved the washing of the reaction mixture with 
distillated water, extraction with dichloromethane and purification of the crude residue 
by silica gel column using CH2Cl2 as eluent. The first fraction to be obtained was the 
starting porphyrin 1 and the second fraction was identified as compound 7 (the yield of 
this step was not determined).  
The structure of the new porphyrin derivative 7 was confirmed by UV-vis, 1H and ESI-
MS. In 1H NMR spectrum it is possible to identify the same signals as for the mono 
substituted ethylenediamine at δ 1.47, 3.21 and 3.78 ppm, plus the characteristic signals 
from the porphyrinic ring at δ 8.88 and 9.03 ppm, suggesting that the reaction was 
accomplished as pretended. Compound 7 UV-vis spectra present a Soret band at 415 nm 
solvent solvent 
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and three Q-bands at 508, 585 and 658 nm. By ESI-MS it was observed one ion at m/z 
1115.2, corresponding to the m/z of the pretended compound.  
For the reaction of the porphyrin with the spacer with artesunate it was necessary to 
remove the protecting group from compound 7. The reaction was performed in 
trifluoroacetic acid (TFA) and dichloromethane at room temperature (scheme 2 iii)). The 
evolution of the reaction was controlled by TLC and it was stopped when it was observed 
the total consumption of the starting derivative, suggesting a total deprotection of the 
amine group (compound 8). The structure of the new porphyrin derivative 8 was 
confirmed by UV-vis, 1H NMR and ESI-MS. 1H NMR spectrum is very similar to 
previous compound, but shows clearly the absence of the signal corresponding to the 
BOC group at δ 1.45 ppm. The UV-vis spectrum of the compound 8 shows a Soret band 
at 414 nm and three Q-bands at 508, 585, 658 nm. The ESI-MS spectrum presents the ion 
at m/z 1015.1, corresponding to the desired compound.  
After the removal of the protecting group from amine, the next step was the reaction 
of artesunate with the porphyrin 8 (scheme 2 iv)). Several experimental conditions in the 
synthesis of compound 9 were tried, in particular the activation of the acid group of 
artesunate with 4-(dimethylamino) pyridine (DMAP) and ethylcarbodiimide (EDC). The 
reaction was performed in CHCl3 at room temperature during 1h30. The reaction was 
controlled by TLC but unfortunately the TLC control did not show any consumption of 
compound 8. 
As the reaction of the drug and the compound 8 was not accomplished the strategy 
adopted was first to react the ethylenediamine with artesunate (scheme 3).  
 
 
Reaction conditions: i) oxalyl chloride, DMF, dry CH2Cl2, 2h at room temperature; ii) EDC, 
DMAP, CHCl3, 1h30 at room temperature; iii) DCC, DMAP, 1h30 at 0ºC. 
Scheme 3 
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The first attempted was the formation of an acyl chloride to form a reactive derivative 
of artesunate (scheme 3 i)) (87). The reaction was executed in dry CH2Cl2 at room 
temperature in the presence of oxalyl chloride, ethylenediamine and DMF. In the second 
attempt it was reacted ethylenediamine, artesunate, EDC and DMAP at room temperature 
in CHCl3 (scheme 3 ii)). The same reaction was performed at 0ºC but it was substituted 
EDC by carbodiimide (DCC) (scheme 3 iii)). All the reactions were controlled by TLC 
and ESI-MS. By TLC the evolution of reaction was difficult to monitor, and it was 
performed an ESI-MS spectrum that do not show the presence of the ion corresponding 
to the pretended compound. 
The failure of this reactions may be due to the fact that EDC and DCC react with 
carboxylic acid groups to form an active O-acylisourea intermediate (scheme 4, A). This 
intermediate can proceed by different pathways depending for example in the 
concentration of the reagents (88). The same compound is easily displaced by 
nucleophilic attack from primary amino groups and it is formed an amide bond with the 
carboxyl group original from artesunate (scheme 4 i)). An EDC/DCC by-product is 
released as a urea derivative (scheme 4, B). Once the derivative A is unstable, failure to 
react with the amine results in the hydrolysis of the intermediate, there are the 
regeneration of the carboxyls and the release of an N-unsubstituted urea (scheme 4, C) 
(88). The formation of the N-acylisourea is due to a rearrangement of A and can occur in 
excess of carbodiimide (88,89). In fact, from the ESI-MS spectrum of the reactions ii) 
and iii) from scheme 3 it was verified the presence of the peak corresponding to the m/z 
of the derivative C (m/z 540.4). 
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Scheme 4 
The porphyrin derivatives were synthetized in order to obtain new compounds that 
could have anti-malarial properties. These porphyrinic derivatives can act as oxidants and 
thus can be used as pro oxidant agents toward membrane lipids. So in the next section it 
will be presented the results from lipid peroxidation induced by the new porphyrin 
derivatives synthetized (compounds 1 to 6). For that we used liposomes as biomimetic 
systems of cell membranes.  
2. Evaluation of the effect of porphyrin derivatives in lipid peroxidation using 
liposomes of PLPC and dMPC as biomimetic systems of cell membranes  
As it was already mentioned, the main objective of this work was to prepare new anti-
malaria porphyrin conjugates and to evaluate their ability to oxidize membrane 
phospholipids. Lipid oxidation of membranes can induce disruption of parasite membrane 
leading to parasite destruction. The effect of the new porphyrin derivatives in lipid 
peroxidation was evaluated using liposomes with two different phosphatidylcholines: 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (dMPC) (Figure 20 a) and 1-palmitoyl-2-
lineloyl-sn-glycero-3-phosphocholine (PLPC) (Figure 20 b), as biomimetic membranes. 
PLPC is susceptible to oxidation due to the presence of a polyunsaturated hydrocarbon 
chain, the linoleic acid (C18:2, ∆ 9,12), in its constitution. On the other hand, dMPC has 
two saturated fatty acyl chains, (C16:0) that are not predisposed to oxidation. The extent 
of oxidation of PLPC in the presence of metalloporphyrins was monitored by electrospray 
mass spectrometry. Since dMPC was not modified in the presence oxidative conditions it 
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was selected as the internal standard. Therefore, the evaluation of the variation of the 
relative abundance of the [M+H]+ ions of PLPC versus the relative abundance of the 
[M+H]+ ion of dMPC was used to monitor the extent of PLPC oxidation.  
Phosphatidylcholines are the major phospholipids present in cell membranes in 
eukaryotic organisms and the selection of those PC’s species to form liposomes was 
planned in order to achieve a better approach to mimic parasite membrane (57).  
 
Figure 20 – Representation of the structure of dMPC (a)) and PLPC (b)). 
 
Most of the studies by mass spectrometry concerning the oxidation phospholipids are 
related with that class of phospholipids (74,75,90). Lipid peroxidation can be mediated 
by free radicals, namely by oxygen reactive species (ROS) that generate a high range of 
lipid oxidized products (75). Radical hydroxyl (OH●) is one of the most reactive ROS 
(91). Reis, et al (74), studied the radical peroxidation of PLPC by mass spectrometry 
using Fenton conditions to generate OH●. The products identified from lipid oxidation 
included long chain products if the phospholipid chain is preserved and has extra number 
of oxygen atoms, resulting in an increase in phospholipid mass, and short chain products 
if the unsaturated phospholipid is broken down by oxidative cleavage and with formation 
of shortened fatty acyl chains that may have terminal aldehyde or carboxylic groups 
(71,72). These authors observed the formation of long-chain products of PLPC with the 
insertion of one (m/z 774.6), two (m/z 790.6), three (m/z 806.6), four (m/z 822.6) or five 
(m/z 838.6) oxygen atoms in the unsaturated fatty acyl chain (74).  
Having this facts in mind, the extent of oxidation was monitored by electrospray 
ionization mass spectrometry in the positive mode (ESI-MS). In the ESI-MS spectra, the 
unmodified PCs were identified as [M+H]+ ions at m/z 758.6 (PLPC) and m/z 678.5 
(dMPC). Sodium and potassium adducts ([M+Na]+ and [M+K]+ respectively) of 
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unmodified PCs were also identified at m/z 700.5 and m/z 716.5 for dMPC and m/z 780.6 
and m/z 796.5 for PLPC. These ions were identified in all acquired spectra. 
In the systems where oxidation of PLPC occurred we saw the ions corresponding to 
oxidized PLPC namely ions correspondent to PLPC + O (m/z 772.6 and m/z 774.6), PLPC 
+ 2O (m/z 790.6 and m/z 788.6) and PLPC + 3O (m/z 804.6 and m/z 806.6). Furthermore, 
it was possible to observe a decrease in the relative abundance of PLPC during the time 
of reaction in comparison with the relative abundance of dMPC as it is exemplified in 
figure 21 for the iron(III) complex 2. Confirmation of the structural features of lipid 
oxidation products was evaluated by tandem mass spectrometry analysis (vide infra). 
 
Figure 21 - ESI mass spectra of the phospholipid liposomes in the presence of potential 
antimalarial compound 2, after 2h, 4h and 6h of reaction in absence of H2O2. 
 
To evaluate the oxidation capacity of the porphyrin derivatives 1-6, these were 
incubated with phospholipid liposomes at 37 ºC in ammonium hydrogen carbonate buffer 
and the reaction was monitored by ESI-MS at 0 hours and after 2, 4 and 6 hours of 
reaction. All the compounds were incubated with the phospholipids in the presence of 
H2O2 and in its absence. In the case of metalloporphyrins the reactions were performed 
in duplicate either with or without H2O2.  
 
2.1.Evaluation of the oxidation extension after 6h of reaction in the presence of 
compounds 1-6 
The capacity of the free-bases and of the metalloporphyrins 1-6 to oxidize the 
phospholipids was determined by the variation of the relative abundance of [dMPC+H]+ 
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and [PLPC+H]+ at different times. A high extent of PLPC oxidation induced a decrease 
in the relative abundance of PLPC [M+H]+ ion and thus an increase in the ratio 
[dMPC+H]+/[PLPC+H]+. The variation of this ratio for all compounds studied (1-6) after 
the six hours of reaction, in the presence and in the absence of H2O2, is presented in figure 
22.  For all the reactions, the ratio at time 0h (T0) was equal revealing that no oxidation 
occurred and it was used as control.  
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Figure 22 – Variation of [dMPC+H]+/[PLPC+H]+ ratio in the presence of compounds 1 
to 6 with and without H2O2. In figure is represented the significant variations on the ratio 
of the two PCs after 6h of reaction.  
***p<0.001, significantly different between selected conditions. 
 
In the presence of the free-bases 1, 3 and 5, no variation in the ratio 
[dMPC+H]+/[PLPC+H]+ was detected under both conditions (in the presence or absence 
of H2O2). In the presence of the iron complexes 2, 4 and 6, the results showed a different 
situation and in general, a significant increase of phospholipid oxidation occurred after 
six hours of reaction. The increase in the ratio [dMPC+H]+/ [PLPC+H]+ in the presence 
and in the absence of H2O2, after the six hours of reaction is significantly different from 
T0 ratio except for compound 6 in the presence of H2O2. In fact, compound 6 only showed 
a significant increase in that ratio in the presence of O2. From the results obtained it can 
be concluded that the free base porphyrins 1, 3 and 5 were unable to oxidize the 
biomimetic membrane and its oxidation in the presence and in the absence of hydrogen 
peroxide only occurred in the presence of the Fe(III) complexes. In fact, 
metalloporphyrins have been widely used as promoters of organic compounds oxidation, 
namely aliphatic and aromatic hydrocarbons (68,70,92).  
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The mechanism of oxidation by iron porphyrins can be associated to the proposed 
mechanism for CYP, due to the similarity of the catalytic center (68). However, different 
mechanisms of oxidation by iron porphyrins have been proposed, that can involve a 
Fenton-like mechanism (24) and/or high-valent (oxometallo) intermediates (92,93). The 
most accepted mechanism of hydroxylation and epoxidation by biomimetic porphyrinic 
models involves high-valent intermediates namely the porphyrin π-cation radical  
O=Fe(IV) Por●+ (24,93,94). However, the porphyrin π-cation radical  can also be 
involved in the formation of radical species which may start the lipid peroxidation by 
radical chain reactions (92,95).  In fact, polyunsaturated lipids are particularly susceptible 
to oxidation and as they are sensitive to catalysis by metals, small concentrations of 
metalloporphyrins may initiate lipid peroxidation by a radical chain process (24). So, in 
the lipid oxidation mediated by metalloporphyrins can be involved a  radical chain process 
or the direct interaction of the high-valent intermediate with unsaturated aliphatic chains 
(68). This topic will be further discussed in section 2.5 together with the proposed 
structures for the PLPC oxidation products. 
 
2.2.Evaluation of the oxidation extension after 2 hours of reaction in the presence 
of compounds 2, 4 and 6 with proved oxidation ability 
In order to evaluate if the differences detected for compounds 2, 4 and 6 after six 
hours of reaction were also patent in the earlier stage of oxidation, their efficacy was 
determined after 2h of reaction in the presence and in the absence of H2O2 (Figure 23).
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Figure 23 - Variation of [dMPC+H]+/[PLPC+H]+ ratio in the presence of compounds 2, 
4 and 6 with and without H2O2. In figure is represented the significant variations on the 
ratio of the two PCs after 2h of reaction. 
***p<0.001 
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The results showed that the increase in the ratio [dMPC+H]+/ [PLPC+H]+ is only 
significantly different from the T0 ratio for compound 2 in the presence of H2O2 and for 
compound 4 in the absence of H2O2.   For the other conditions, namely for compounds 4 
in the absence of H2O2 and for 6 in the presence and in the absence of H2O2, it was verified 
a small increase in the oxidation ratio but it was not considered statistically significant. 
Interesting, for compound 2 the ratio [dMPC+H]+/[PLPC+H]+ in the absence of H2O2 was 
equal to the ratio obtained at T0.  
In the oxidation mechanism proposed for CYP (see Figure 10), it was referred that the 
iron(III) complex can also interact with monoxygen donors like peroxides by a peroxide 
shunt pathway, that can lead to the formation of the active intermediate [O=Fe(IV) Por]●+ 
↔ (Porphyrin)Fe(V)=O] complex. Probably, with complex 2, the higher oxidation ratio 
obtained in the presence of H2O2, can be justified by the peroxide shunt pathway to occur 
more quickly in the first stage of oxidation than the process involving molecular oxygen 
(see discussion below) (96). With the other complexes the difference between the two 
events is not so notorious.  
 
2.3.Global comparison of the oxidation extension in the presence of complexes 
2, 4 and 6 
After finding out which porphyrin derivatives have the ability to oxidize membrane 
phospholipids, it was evaluated if there were differences on oxidation by these 
compounds. As it is represented in figure 24, compound 2, the metal complex of the 
starting porphyrin (TF5PP), showed a significant increase in oxidation compared with the 
compounds 4 and 6 in the presence and absence of H2O2 after six hours of reaction. 
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Figure 24 - Variation of [dMPC+H]+/[PLPC+H]+ ratio in the presence of compounds 2, 
4 and 6 with and without H2O2. ***p<0.001, **p<0.01, *p<0.05 
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In fact, after that time compound 2 showed a higher increase of 
[dMPC+H]+/[PLPC+H]+ ratio than compounds 4 and 6. While compound 2 had a 
maximum increase of about 0.40 of the [dMPC+H]+/[PLPC+H]+ ratio, the increase for 
compounds 3 and 4 did not exceed 0.15. 
Compounds 4 and 6 showed a similar increase of the [dMPC+H]+/[PLPC+H]+ ratio, 
both in the presence and absence of H2O2. Although it was observed that compound 2 
promoted the highest percentage of oxidation after 6 hours of reaction in the absence of 
H2O2 and compound 4 presented a higher percentage of oxidation in the first two hours 
of reaction under the same conditions. Additionally, in the presence of H2O2 compound 
2 showed a higher increase in PLPC oxidation when compared with compound 6 after six 
hours of reaction. Thus, in general compound 2 after six hours of reaction proved to be 
the more effective to oxidize membrane phospholipids than the conjugates 4 and 6.  
It is important to have in mind that the drugs used in this work are already used in 
malaria treatment. So, their incorporation in the porphyrinic nucleus can have an 
important role in the oxidation of membrane phospholipids but also prevent hemozoin 
formation (29). The mechanism of action of the drugs used in this work involves the 
interaction with the heme group, inhibiting the polymerization of hemozoin (31). Some 
strains of the parasite had already developed resistance for the drugs as primaquine and 
mefloquine (37). However, the fact that the drug is now linked to the porphyrin, can lead 
to a new pharmaceutical approach since the parasite may not have defense mechanisms 
for these new compounds. Plus, the metalloporphyrins in addition to its the role in parasite 
membrane oxidation may also work as a drug transporter (35).  
The free base porphyrins derivatives 1, 3 and 5 did not show any influence on the 
phospholipid oxidation and this fact does not preclude its activity against malaria parasite. 
As referred before, some porphyrins have already been tested against malaria but in the 
mechanism of action was not referred the possibility that porphyrins could act also via a 
direct oxidation of the membrane parasite. Porphyrins are usually referred to interact with 
the heme group by π interactions, inhibiting the malaria parasite pigment formation 
(41,50,51), leading the heme group available, that is responsible by the destruction of the 
parasite membrane. 
The synthesis of derivative with the drug artesunate was not accomplished, although 
it should be given attention to that. Artesunate is a derivative of artemisinin and booth 
drugs are already being used in malaria treatment (33,97). In the parasite, it is necessary 
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that the free heme interact with these compounds to activate the drug, promoting then the 
formation of free radicals that may initiate parasite lipids oxidation (32). The linkage of 
this drug to the porphyrin may have led to a higher oxidation of PLPC than the other 
drugs tested. 
 
2.4.Evaluation of the oxidant capacity of compound 2 in combination with the 
drugs mefloquine and primaquine 
In order to evaluate if the oxidant efficacy of complex 2 is not affected by presence of 
mefloquine and primaquine, new experiments involving the combination of complex 2 
and those drugs were performed in the presence and in the absence of hydrogen peroxide. 
Extra experiments with free drugs in the presence and in the absence of H2O2 were also 
performed in order to verify if these combinations have the capacity to oxidize PLPC 
(Figure 25a). Additionally, was performed a test only with H2O2 to prove that this oxidant 
alone was not able of oxidize phospholipids and a test under Fenton conditions in order 
to compare  the rate of phospholipid oxidation in the presence of the metalloporphyrins 
and under Fenton conditions (Figure 25b). 
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Figure 25 – Variation of [dMPC+H]+/[PLPC+H]+ ratio by the presence of compound 2 
and its combination with primaquine and mefloquine and in the presence of free drugs (a) 
and comparing with H2O2 and Fenton mechanism (b). 
***p<0.001 
 
The results in Figure 25a) show that the drugs alone or in combination with H2O2 were 
not able to promote any PLPC oxidation. Oxidative events in the presence of mefloquine 
and primaquine were only detected when compound 2 was also present. The results 
summarized in figure 25 b) confirmed that H2O2 alone or under Fenton conditions after 6 
hours of reaction were also not able to promote PLPC oxidation. The presence of the 
drugs in combination with compound 2 showed a similar [dMPC+H]+/[PLPC+H]+ ratio 
when compared with the one of compound 2 both in the presence and the absence of H2O2 
(figure 25 b). These results suggest that the efficiency of the porphyrin is not affected by 
the drugs. Plus, compound 2 alone present a higher [dMPC+H]+/[PLPC+H]+ ratio when 
compared with the ratio in the presence of H2O2. However, this difference was only 
significant in case of the compound 2 with the drug primaquine.  
In all the reactions with the metalloporphyrins in the presence of H2O2 it was verified 
a lower PLPC oxidation when compared with the tests in the absence of hydrogen 
peroxide, after the six hours of reaction. Plasmodium as a parasite, during the invasion of 
the erythrocytes, has access to a rich source of nutrients and it is protected from the 
immune system of the host (5). For that, it is not expected an elevated production of H2O2 
in red blood cells during the parasite invasion.  
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In figure 26 it is represented all the reactions where it was actually observed PLPC 
oxidation.  
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Figure 26 – Variation of [dMPC+H]+/[PLPC+H]+ ratio in the presence of all 
metalloporphyrins during 2h, 4h and 6h of reaction (error bars not shown).  
 
It is possible to see the most efficient systems for PLPC is based on compound 2 or on 
its combination with the drugs primaquine and mefloquine not covalently linked the in 
the absence of H2O2. Interesting, after 4 hours of reaction the best system is the 
combination of compound 2 with primaquine.  
 
2.5.Identification of PLPC oxidation products in the presence of porphyrins: 
possible reaction pathways 
The new metalloporphyrins synthetized in this work showed to have oxidant activity 
toward phospholipids, namely PLPC. Mass spectrometry analysis allowed the 
identification of phosphatidylcholine oxidation products, corresponding to the insertion 
of: i) one oxygen atom (m/z 774.6) and one oxygen atom with 2 Da mass decrease (m/z 
772.6); ii) two oxygen atoms (m/z 790.6) and two oxygen atoms with 2 Da mass decrease 
(mz 788.6); iii) three oxygen atoms (806.6) and three oxygen atoms with 2 Da mass 
decrease (804.6). These type of products were already described by our and other groups 
(74,98,99) and may be formed in different oxidation conditions namely non-enzymatic 
methods, like hydroxyl radical generated from H2O2/Fe2+ or H2O2/Cu2+ systems, and 
enzymatic conditions using lipoxygenase or myeloperoxidase to mimic in vivo conditions 
(90). The mechanism of lipid peroxidation starts with hydrogen abstraction from an 
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allylic position affording a radical stabilized by resonance. The hydrogen abstraction can 
be mediated by radicals or by the Fe3+ ion from enzymes like CYP (75). 
Several mechanisms of oxidation mediated by the Heme group, released from 
myoglobin or hemoglobin, were proposed (24). The mechanisms of oxidation by the 
metalloporphyrins used in this work may be similar to those observed to heme-group and 
to other enzymes like CYP that have the same catalytic center. In order to clarify the type 
of mechanism involved in the PLPC oxidation, the products obtained were identified by 
tandem mass spectrometry.  
The oxidation products formed in the reactions performed with the iron(III) complexes 
in the presence or in the absence of H2O2 were the same as it was confirmed by MS/MS 
spectrum.  In figure 27 is represented the MS/MS spectrum of the product with the m/z 
790.6 formed in the presence and in absence of H2O2. In both spectra is observed two 
mainly ions apart from the ion corresponding to the loss of the phosphatidylcholine head 
(m/z 184.6). Those ions correspond to the loss of water (m/z 772.6) and H2O2 (m/z 756.6).  
 
 
Figure 27 – MS/MS spectra of oxidation product at m/z 790.6 in the presence (a) and 
absence of H2O2 (b). 
In fact, the most abundant oxidation product formed was the product with the m/z 
790.6, and were identified mainly two ions that correspond to the loss of water and 
hydrogen peroxide. The last neutral loss is typical of hydroperoxy derivatives and the loss 
of water of hydroxyl derivatives (74). So, the ion at m/z 790.6 may correspond to different 
structures (figure 28), for example the derivatives bearing two hydroxyl groups, an epoxy 
and a hydroxyl function and a hydroperoxide derivative. However, other structures can 
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be assumed. The second most abundant oxidation product formed during the six hours of 
reaction was the ion at m/z 772.6 which correspond to the insertion of one oxygen atom 
minus two hydrogen atoms. Two possible structures of this ion are represented on the 
figure below.  
 
Figure 28 – Proposed structure to the oxidation products with m/z 772.6 (a and b) and 
m/z 790.6 (c, d and e). 
It is worth to highlight that in these studies the PLPC oxidation was observed either in 
the presence or in the absence of H2O2, meaning that in this last case the molecular oxygen 
present in the reaction was involved in the process. In fact, the oxidation mediated by 
Fe(III) porphyrins in the presence or the absence of hydrogen peroxide does not involve 
the same mechanisms. It is well established that Fe(III) porphyrins can react with 
hydrogen peroxide to form species of higher oxidation states [(Porphyrin)Fe(IV)=O] •+ 
↔ [(Porphyrin)Fe(V)=O] (68,70,94,95). In figure 29 is represented a possible mechanism 
for the oxidation process mediated by Fe(III) porphyrins in the presence of H2O2. After 
the interaction of the porphyrin with hydrogen peroxide, the reaction may follow two 
different pathways (reactions 2 and 3). It was proposed that oxygen-oxygen bond, from 
the product formed in reaction 2, may undergo a homolytic cleavage that produce a 
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hydroxyl radical (100), or a heterolytic cleavage that produce the iron(IV) π-radical cation 
species and water. Some evidences have already been reported that these two cleavages 
may occur simultaneously and the separation between the two pathways may depend on 
the composition of the porphyrin, the axial ligands and the oxidant (101). So, the 
porphyrinic cation radical may react with the substrate, in this case with phospholipids, 
and lead to double bond epoxidation or to allylic hydroxylation of those. In addition the 
hydroxyl radical generated under these conditions may induce radical peroxidation of the 
phospholipids, similarly as previously observed in the oxidation of phospholipids under 
Fenton reaction conditions (102). 
 
Figure 29 - Proposed mechanism for oxidation of phospholipids as substrate mediated 
by iron (III)-chloride porphyrins in the presence of H2O2 (adapted from (68)).  
 
As it was mentioned, the mechanism of oxidation in the absence of hydrogen peroxide 
must involve the oxygen molecular from the reaction medium. Maldotti et al.(103), 
described a possible mechanism of oxidation by Fe(III) porphyrins that involves the 
reduction of the metal center as well as the formation of radical species by photo 
activation. So, these authors showed that the Fe(III) porphyrins inside micelles can be 
reduced to Fe(II) porphyrins with the concomitant oxidation of axial ligand to a radical 
specie. In scheme 5 is represented the mechanism proposed by these authors. The radical 
(Cl●) may abstract the allylic hydrogen atom from the diene system affording radical 3 
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stabilized by resonance. Then, O2 can react with the Fe(II) porphyrin leading to the 
formation of intermediate 5 that after reaction with the radical substrate can afford for 
example a keto product. In fact, one of the most abundant oxidation products observed 
during the oxidation by metalloporphyrins is the keto derivative product (m/z 772.6). 
However, the radical resulting from the abstraction of the hydrogen atom from the allylic 
position of the substrate may also react with molecular oxygen, starting a radical chain 
reaction.  
 
 
Scheme 5 
 
Like this, the exact mechanism of oxidation by the porphyrin derivatives synthetized 
in this work is not well established. These compounds may undergo to different reactions, 
producing different oxidation products. The porphyrins may interact directly with the 
substrate, leading to epoxidation or hydroxylation of the same, but also can lead to the 
formation of radicals that may start a radical chain reaction. The mechanism of oxidation 
by these porphyrins in the presence or the absence of hydrogen peroxide is different, but 
the oxidation products observed were the same.  
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1. Reagents and equipment  
Commercial reagents for the synthesis of porphyrin derivatives did not suffer further 
purification. Reactions were followed by TLC, using plastic sheets covered by silica gel 
60 F250. After elution some of the TLC were observed at UV light at 254 or 366 nm. UV-
vis spectra were register in a spectrophotometer UV-2501PC Shimadzu in glass cells with 
1 cm of optical path. NMR spectra of 1H, 19F and 13C were register in an equipment Bruker 
Avance 300 MHz (300.13 MHz for 1H and 282.38 MHz for 19F) or Avance 500 MHz 
(125.77 MHz for 13C). Solvent used to acquiring of the spectra was deuterated chloroform 
and tetramethylsilane (TMS) as internal reference.  
Purification of reactional mixtures were performed by column with silica gel 60 
(0.063-0.200 nm) from Merck. Preparative thin-layer chromatography was carried out on 
20x20 cm glass plates and previously coated with silica gel 60 from Merck, having a 
thickness of 0.75 mm and activated on an incubator for 12h.  
Phospholipid internal standards 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(dMPC) and 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine (PLPC) were 
purchased to Avanti polar lipids, Inc (Alabaster, AL, USA), and used without further 
purification. Chloroform and methanol were purchased from Fisher Scientific Ltd. 
(Leicestershire, UK). FeCl2 and H2O2 (30%, w/w) were acquired from Merck (Darmstadt, 
Germany). Mili-QH2O used was filtered through a 0.22-mm filter and obtained using a 
Milli-Q Millipore system (Milli-Q plus 185). Ammonium hydrogen carbonate buffer (5 
mM, pH 7.4) was purchased from (Riedel-de Haën, Germany) and prepared in Milli-Q 
water. Drugs mefloquine, primaquine and artesunate were synthetized by the organic 
chemistry group of farmanguinhos - fiocruz (Brazil) and used without further purification. 
 
2. Synthesis of 5,10,15,20-tetrakis(pentafluorophenyl)porphyrin (TF5PP) 
derivatives  
All the porphyrin derivatives were obtained from TF5PP 
(compound 1).  For this work this porphyrin was gently 
provided by Ana Gomes.   
UV-vis (CHCl3): λmax (log ε) 413 (5.51), 506 (4.31), 540 (3.38), 
583 (3.69), 638 (2.63) nm. ESI: m/z =974.1. 
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2.1.Synthesis of compound 3 
The synthesis of this conjugate required a previous deprotection of the drug 
primaquine. In a round bottomed flask containing a magnetic stirring bar were added 250 
mg of protected primaquine and 3 mL of distillated water. The pH was adjusted to 11 
with a solution of NaOH 0.5 M. The flask was maintained at room temperature during 
two hours. Primaquine was extracted with dichloromethane.  
2.1.1. Coupling reaction of compound 1 with primaquine 
Primaquine obtained from previous reaction was added to a round bottomed flask 
containing compound 1 (100 mg, 0.103 mmol), potassium carbonate (1 eq) and toluene 
(5 mL). The mixture was heated at 120ºC for 18h at reflux. After reaching room 
temperature, the mixture was washed with distilled water and extracted with CH2Cl2. The 
combined organic extracts were evaporated under reduced pressure and the crude mixture 
was fractioned in a silica gel column, using CH2Cl2 as eluent. The first fraction observed 
was compound 1 and the second was the pretended compound (compound 3).  
η= 66.5 %. 1H NMR (300 MHz, CDCl3): δ 
9.01 (d, J = 4.8 Hz, 2H), 8.84 – 8.92 (s, 4H), 
8.85 (d, J = 4.8 Hz, 2H), 8.58 (dd, J = 4.2, 
1.6 Hz, 1H), 7.96 (dd, J = 8.3, 1.6 Hz, 1H), 
7.32 (dd, J = 8.3, 4.2 Hz, 1H), 6.40 and 6.39 
(AB, J = 2.5 Hz, 2H), 4.27 – 4.36 (m, 1H), 3.90 (s, 3H), 3.70 – 3.77 (m, 2H), 1.93 – 2.04 
(m, 4H), 1.44 (d, J = 6.4 Hz, 3H), -2.91 (s, 2H). 19F NMR (282 MHz, CDCl3): -184.75 – 
-184.45 (m, 6F, m-F), -183.83 (d, J = 16.7 Hz, 2F, m-F), -174.5 – -174.50 (m, 3F, p-F), -
163.86 – -163.70 (m, 2F, o-F), -159.70 – -159.45 (m, 6F, o-F) ppm. 13C NMR (126 MHz, 
CDCl3): δ 20.78, δ 27.80, δ 33.87, δ 48.02, δ 48.90, δ 55.29, δ 91.85, δ 96.97, δ 99.33, δ 
103.24, δ 115.75, δ 121.98, δ 129.48, δ 130.01, δ 134.92, δ 135.44, δ 136.57, δ 138.58, δ 
141.22, δ 143.26, 145.57, 147.54, δ 159.49 ppm. UV-vis (CHCl3): λmax (log ε) 415 
(5.17), 508 (4.11), 585 (3.63) nm. ESI: m/z =1214.3.  
2.2.Coupling reaction of compound 1 with mefloquine 
A 50 mL round-bottomed flask containing a magnetic stirring bar was charged with 
compound 1 (100 mg; 0.103 mmol), mefloquine (194.2 mg; 0.513 mmol) and NaH (1 
eq) in toluene (5 mL). The mixture was heated at 120ºC for 72h at reflux. After reaching 
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room temperature, the mixture was washed with distilled water and extracted with 
CH2Cl2. The combined organic extracts were evaporated under reduced pressure and the 
crude mixture was fractioned in a silica gel column, using first CH2Cl2 as eluent.  The 
second fraction recovered was the pretended compound (compound 5). Other fractions 
observed resulted from the substitution of more than one fluorine atom by mefloquine.  
η = 47.2 %. 1H NMR (300 MHz, CDCl3): δ 
8.90 (s, 4H), 8.86 and 8.82 (AB, J= 4.8 Hz, 
4H), 8.58 (d, J = 8.0 Hz, 1H), 8.33 (s, 1H), 
8.30 (d, J= 8.0 Hz, 1H), 7.90 (t, J= 8.0 Hz, 
1H), 6.43 (d, J = 4.9 Hz, 1H), 3.31 – 3.40 (m, 
1H), 3.16 – 3.26 (m, 1H), 2.67 – 2.79 (m, 
3H), 2.03 (d, J= 10.8 Hz, 2H), 1.42 – 1.80 (m, 4H). 19F NMR (282 MHz, CDCl3): δ -
83.35 (s, 3F), -90.87 (s, 3F), -159.76 – -159.52 (m, 6F, o-F), -160.44 – -160.28 (m, 2F, o-
F), -174.23 – -174.45 (m, 3F, p-F), -178.16 – -178.35 (m, 2F, m-F), -184.32 – -184.56 
(m, 6F, m-F). 13C NMR (126 MHz, CDCl3): δ 23.00, δ 27.74, δ 23.92, δ 46.95, δ 61.22, 
δ 68.18, δ 103.56, δ 104.09, δ 115.51, δ 115.94, δ 120.11, δ 122.30, δ 124.55, δ 126.78, 
δ 128.28, δ 128.82, δ 130.92, δ 136.56, δ 141.39, δ 144.14, δ 145.53, δ 147.44, δ 162.94, 
δ 167.82 ppm. UV-vis (CHCl3): λmax (log ε) 413 (5.43), 507 (4.28), 583 (3.74), 637 
(3.11) nm. ESI: m/z =1332.87. 
 
2.3.Synthesis of Fe(III) complexes of compounds 1, 3 and 5 
The synthetic approach for the synthesis of Fe(III) complexes of the three different 
compounds followed the same procedure. In a 50 mL two headed round-bottomed flask 
containing a magnetic stirring bar was added compound 1 (100 mg, 0.103 mmol), DMF 
(10 mL) and pyridine (1 mL). The solution was bubbled with nitrogen for 10 min and 
then it was added the FeCl2 (246.2 mg). The reaction was performed in reflux at 140ºC 
for 24h under inert atmosphere. After 24h the DMF was distilled under reduced pressure 
with the addition of small amounts of toluene to help the elimination of DMF. After 
almost all of the DMF was evaporated, the mixture was washed with distilled water and 
extracted with CH2Cl2. The products were obtained pure after purification by preparative 
TLC using a mixture CH2Cl2/MeOH (100:5), followed by crystallization in a 
hexane/CH2Cl2 mixture.  
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η = 65.4 %.  
UV-vis (CHCl3): λmax (log ε) 412 (4.90), 503 (3.92), 630 
(3.56) nm.  
ESI: m/z = 1027.9. 
 
 
η= 14.4 %.  
UV-vis (CHCl3): λmax (log ε) 416 (4.73), 
506 (3.94), 634 (3.60) nm.  
ESI: m/z =1267.73. 
 
 
η= 13.5 %.  
UV-vis (CHCl3): λmax (log ε) 413 (4.54),   
506 (3.54), 628 (3.22) nm. 
ESI: m/z= 1386.70. 
 
 
 
 
2.4.Attempts to conjugate compound 1 with artesunate 
2.4.1. Protection of ethylenediamine with di-tert-butyl dicarbonate (BOC) 
In a two headed rounded flask containing a magnetic stirring bar was added 16 mL of 
ethylenediamine and 25 mL of tetrahydrofuran (THF). The solution was cooled down to 
-10ºC. The, BOC (2.5 mg) was dissolved in THF (12.5 mL) and it was added dropwise 
to the solution of amine during 30 min (104). The reaction was stirred overnight at room 
temperature. THF was dried under reduced pressure and the mono substituted 
ethylenodiamine was extracted with dichloromethane. The compound isolated as an 
yellow oil.  
η= 81 %. 1H NMR (300 MHz, CDCl3): δ 3.16 (q, J= 5.9 Hz, 
2H), δ 2.79 (t, J= 5.9 Hz, 2H), δ 1.45 (s, 9H), ppm.  
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2.4.2. Functionalization of compound 1 with mono substituted ethylenediamine 
A 50 mL round-bottomed flask containing a magnetic stirring bar was charged with 
the TF5PP (75 mg; 0.0767 mmol), mono-substituted ethylenediamine (9.1 mg; 0.057 
mmol), potassium carbonate (10.6 mg, 0.0767 mmol) and toluene (5 mL). The mixture 
was heated at 120ºC for 72h at reflux. During this period, it was added the same amounts 
of mono substitued ethylenediamine and potassium carbonate two more times, once it 
was observed much starting compound (monitored by TLC). The flask was allowed to 
cool at room temperature, the solvent was distilled under reduced pressure and the 
compound was purified by column chromatography using dichloromethane as eluent. The 
desired conjugate (compound 7) was obtained from the second fraction.  
UV-vis (CHCl3): λmax (log ε) 415 
(5.29), 508 (4.16), 585 (3.65), 658 
(2.83). 1H NMR (300 MHz, CDCl3): 
δ 8.97 (d, J=4.7, 2H), δ 8.79 – 8.85 
(m, 6H), δ 3.72 – 3.80 (m, 2H), δ 3.49 
– 3.58 (m, 2H), δ 1.47 (s, 9H), δ – 
2.98 (s, 2H) ppm. 
 
2.4.3. Deprotection of compound 7 
In a two headed flask with a magnetic stirring bar was added the porphyrin 
functionalized with ethylenediamine, dichloromethane (1 mL) and TFA (5 eq.) at room 
temperature. The reaction was controlled by TLC and when it was not observed release 
of gas it was stopped. The 1H NMR confirmed the total deprotection of the amino, and 
the yield of compound 8 was not calculated.  
UV-vis (CHCl3): λmax (log ε) 414 (5.36), 
508 (4.16), 585 (3.60), 658 (2.98). 1H NMR 
(300 MHz, CDCl3): δ 9.03 (d, J= 4.7 Hz, 
2H), δ 8.85 – 8.94 (m, 6H), δ 3.75 – 3.84 (m, 
2H), δ 3.17 – 3.25 (m, 2H), δ -2.91 (s, 2H) 
ppm. 
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2.4.4. Coupling reaction of compound 8 with artesunate 
In a 50 mL rounded flask containing a magnetic stirring bar was placed the porphyrin 
(5mg, 0.00513 mmol), artesunate (18.9 mg, 0.049 mmol), ethylcarbodiimide (EDC) (1,5 
eq, 0.0736 mmol), 4-(dimethylamino)pyridine (DMAP) (4 eq, 0.196 mmol) in CHCl3 
(1mL). The reaction was executed at room temperature for 1h30 and after this time was 
controlled by TLC and it was not observed the formation of the pretended compound.  
2.4.5. Coupling reactions of artesunate and ethylenediamine 
Other attempts were also performed for the formation of compound 1 and artesunate 
conjugate, by reacting artesunate with ethylenediamine. In a 50 mL round-bottomed flask 
containing a magnetic stirring bar was added artesunate (50 mg, 0.13 mmol), EDC (1,5 
eq, 0.193 mmol), DMAP (4 eq, 0.516 mmol), ethylenediamine (13µL) and CHCl3 (1 mL) 
at room temperature. The reaction was controlled by TLC and it was not observed the 
formation of pretended compound. The same reaction was performed at 0ºC but it was 
substituted EDC by carbodiimide (DCC) (40 mg, 0.194 mmol), maintaining the other 
reactional conditions.  
It was tested another way to achieve the reaction between ethylenodiamine and 
artesunate. In a 50 mL round-bottomed flask containing a magnetic stirring bar was added 
artesunate (50 mg), DMF (0.13 mmol), oxalyl chloride (2.5 mmol), ethylenediamine (10 
eq) and dry CH2CL2 (105). The reaction was executed at room temperature for 2h and 
after this time was controlled by TLC and once more it was not observed the formation 
of the pretended compound.  
 
3. Phospholipid oxidation by porphyrins derivatives 
3.1.Sample preparation and phospholipid oxidation by porphyrinic compounds 
Stock solutions of PLPC, dMPC, compounds 1 to 6, mefloquine and primaquine were 
prepared in chloroform (1mg/mL). Then, 62.5 µg PLPC (final concentration of 1.32 mM) 
and 14 µg of dMPC (final concentration of 0.33 mM) were mixed. dMPC is a standard to 
control the extension of oxidation and it was added in a concentration equal to a quarter 
of PLPC concentration. Additionally 0.5 µM of each porphyrinic compound were mixed 
to the previous solution and dried under nitrogen stream. The ammonium hydrogen 
carbonate buffer (5mM, pH=7.4) was added to each vial until perform a final volume of 
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62.5 µL. All of the vials were submitted to the same conditions of reaction. Furthermore, 
it was performed a test with H2O2 with all different porphyrin compounds. All the 
procedure was the same but it was added the H2O2 (1 mM), prepared in Milli-Q water, 
after the addiction of the buffer, until perform a final volume of 62.5 µL. To form 
liposomes, the vials were vortex-mixed during 10 min, sonicated for 15 min on ultrasound 
(Selecta Ultrasons) followed by more 5 min on vortex. The samples were incubated at 
37ºC and the oxidation was monitored by mass spectrometry (ESI) every 2 hours in a full 
time of six hours. For negative control there were prepared liposomes with only H2O2 and 
free compounds namely mefloquine and primaquine.  
3.2.Q-TOF conditions 
The MS and MS/MS studies were carried out in the positive mode on a Q-TOF2 
instrument (Micromass, Manchester, UK). Samples were introduced through direct 
infusion into the electrospray source at a flow rate of 10 μL min−1. The cone voltage was 
set at 30 V and capillary voltage applied to the needle at 3 kV. Source temperature was at 
80 °C and desolvation temperature at 150 °C. The resolution was set to about 9000 
(FWHM). MS/MS were acquired by collision-induced decomposition (CID), using argon 
as the collision gas (measured pressure in the penning gauge ∼6×10-5 mbar). The collision 
energy used was 25 to 30 eV. Data acquisition was carried out with a MassLynx 4.0 data 
system. 
 
3.3.Statistical analysis 
The results are presented as mean values and their standard deviations (mean ± SD) 
for each experimental group. Two-way analysis of variance (ANOVA) was used with the 
Bonferroni pos-test to evaluate significant differences among samples. A value of p<0.05 
were considered to be statistically significant. Statistical analysis were performed using 
GraphPad Prism 5 software.   
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In this work were prepared new porphyrinic conjugates bearing drugs already used in 
malaria treatment. It was expected that these new conjugates have oxidative power toward 
membranes and that can act as drug delivers. The synthesis of the new porphyrin 
derivatives was accomplished with the drugs mefloquine and primaquine, being the 
nucleophilic substitution of one para-fluorine atom in 5,10,15,20-tetrakis 
(pentafluorophenyl)porphyrin  the key step of the synthetic strategy proposed. Due to the 
structure of artesunate the reaction could not follow the same procedure, and involved 
more steps of reaction that unfortunately were not successful. Also, using conventional 
procedures, the Fe(III) complexes of the compounds 1, 3 and 5 were synthetized  and 
characterized.  
Lipid peroxidation induced by all the different porphyrinic compounds (1 to 6), in 
liposomes as biomimetic systems of cellular membranes, was monitored by ESI-MS and 
the products of oxidation identified by tandem mass spectrometry. By the ratio 
[dMPC+H]+/[PLPC+H]+ it was possible to evaluate the extension of reaction. All the 
metalloporphyrins tested in this work (2, 4 and 6) showed to be able to oxidize 
phospholipids in the presence and absence of H2O2, although with different efficacy. 
Compound 2 showed to be the one with better results of oxidizing PLPC, comparing with 
the compounds 4 and 6 in the presence and the absence of hydrogen peroxide. It was also 
verified that the drugs alone have no capacity of oxidizing phospholipids, and its 
combination with the compound 2 did not affect the oxidation promoted by this 
compound. The most abundant products formed by porphyrin oxidation were those with 
m/z 772.6, m/z 790.6, m/z 788.6 and m/z 806.6, that correspond to the insertion of one to 
three oxygen atoms in the linoleic acid of PLPC. The mechanism of oxidation by these 
compounds is complex, it was verified that the mechanism is not always the same, 
porphyrins may interact directly with the substrate and promote its oxidation, or can 
produce radical species that are able to start radical chain reactions. 
As future perspectives it was interesting to synthetize the compound 9 that was not 
accomplished in this work, once artemisinin nowadays is the drug that is mostly used 
against malaria. The confirmation of mechanism of oxidation by the porphyrins in the 
absence of H2O2 is also an important perspective to a better understanding of the 
comportment of these compounds in vivo. Some tests with some of the porphyrins used 
in this work are already being carried out by the group of Brazil. 
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